zolbetuximab · Medicine question

How does zolbetuximab destroy CLDN18.2-positive cells?

iatroX medicinesPublished 8 November 2026

The answer

Answer

Zolbetuximab targets CLDN18.2 and destroys CLDN18.2-positive cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Sources for this answer

Vyloy powder for concentrate for solution for infusionAstellas Pharma Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 6Document updated 7 May 2026

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

Can zolbetuximab (Vyloy) affect the ability to drive or use machines?How is zolbetuximab (Vyloy) administered, and what is the minimum infusion time?How much polysorbate 80 is present in the 100 mg and 300 mg vials of zolbetuximab (Vyloy)?What concentration of zolbetuximab does Vyloy contain after reconstitution?What is known about the effects of zolbetuximab on male and female fertility?When are nausea and vomiting most frequent during zolbetuximab (Vyloy) treatment combined with fluoropyrimidine- and platinum-containing chemotherapy?

loading page…

Answer

Sources for this answer

More questions about zolbetuximab

Answer

Sources for this answer

More questions about zolbetuximab

zolbetuximab

More clinical questions?